We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall
One woman shares her journey
Activist investor steps up battle over ‘disastrous’ acquisition by world’s biggest genome sequencer
Experiment in Switzerland’s biggest city will assess benefits of regulating supply of the recreational drug
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
UK genomic sequencing group ‘not ruling out’ any options, says chief executive
Companies want incentives to create jobs and stave off competition from China
MHRA chief in talks with watchdogs in Australia, Canada, Singapore and Switzerland to create partnership
Regulators find Danish drugmaker sponsored ‘disguised’ promotional campaign
With the latest credit for research intensive businesses, the government is picking winners by the back door
Chancellor Jeremy Hunt vows to make Britain the ‘best place in Europe’ for tech companies to invest
Unexpected finding suggests popular sweetener could treat autoimmune conditions such as arthritis and diabetes
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Update to Home Office licence will allow London-listed pharmaceuticals group to pursue supply deals
Despite US blacklistings hampering sales and supplies, the real problem is a dwindling market
UK biotech Awakn licences ‘party drug’ to addiction clinics
Company’s shares jump after activist investor launches proxy battle
Acquisition price tag will leave investors feeling queasy
US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity
Scandal spurs questions about quality control at Indian companies and regulatory oversight in poorer countries
Unequal access to jabs in 2021 led to one preventable death every 24 seconds, politicians and activists say
Big names often persuade consumers to swallow price rises
Therapies based on editing of human genomes predicted to have a price tag of $2mn per patient
Also in today’s newsletter, bosses win bigger bonuses for hitting environmental goals
Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn
International Edition
